SuperworthGinkgo Bioworks DNA
- Market cap
- $672.7M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 6.0×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $111.9M
- −47% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −26.0%
Ginkgo Bioworks trades at 6.0× sales. Revenue was $111.9M over the last twelve months, down 47% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $55.4M−17% | $34.8M−65% | $37.9M−53% | $56.2M−30% | $89M+61% | $43.8M+26% | $38.2M+1% | $39.1M−30% | $38.8M−56% | $33.4M−24% | $19.5M−49% | $20.2M−49% | |
| Cost of revenue | $6.9M−72% | $6.6M−78% | $9.2M−59% | $13.7M−24% | $12M+73% | $9.6M+46% | $4.1M−56% | $5.4M−61% | $12.8M+7% | $7.3M−24% | $3.1M−24% | $1.7M−68% |
| Gross profit | $48.5M+16% | $28.1M−59% | $28.7M−51% | $42.5M−32% | $77M+59% | $34.2M+22% | $34.1M+19% | $33.8M−21% | $26M−66% | $26.1M−24% | $16.4M−52% | $18.4M−45% |
| R&D | $156.7M−40% | $117M−34% | $136.5M−16% | $134.2M−7% | $77M−51% | $76.4M−35% | $70.9M−48% | $53.4M−60% | $69.4M−10% | $50.1M−34% | $49.9M−30% | $46.2M−13% |
| SG&A | $82M−81% | $89.2M−27% | $70.3M−37% | $66.3M−35% | $52.3M−36% | $57.3M−36% | $39.7M−44% | $35M−47% | $45M−14% | $46M−20% | $37.8M−5% | $30.8M−12% |
| −$286.4M−56% | −$178.1M−23% | −$178M−18% | −$222.9M+21% | −$55.2M−81% | −$103.6M−42% | −$81M−55% | −$58.2M−74% | −$90M+63% | −$70.8M−32% | −$71.4M−12% | −$58.5M+1% | |
| Interest expense | −$15M | $44M | n/a | −$10.3M−28% | −$9.3M−38% | $31.4M−29% | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | −$302.9M−55% | −$211.9M+13% | −$165.9M−19% | −$217M+25% | −$56.8M−81% | −$107.9M−49% | −$83.2M−50% | −$53.5M−75% | −$80.8M+42% | −$81.4M−25% | −$76.1M−9% | −$57.2M+7% |
| −$22K−21% | −$198K−99% | $31K−62% | $190K+184% | −$375K+1605% | −$325K+64% | $88K+184% | −$283K | $1K | −$643K+98% | −$80K | $128K | |
| Net income | −$302.9M−55% | −$211.7M+21% | −$165.9M−19% | −$217.2M+25% | −$56.4M−81% | −$107.5M−49% | −$91M−45% | −$60.3M−72% | −$80.8M+43% | −$80.8M−25% | −$82.6M−9% | −$46.7M−23% |
| −$6.21−62% | −$4.28+19% | −$3.32−25% | −$4.23+18% | −$1.08−83% | −$2.00−53% | −$1.68−49% | −$1.10−74% | −$1.45+34% | −$1.42−29% | n/a | n/a | |
| 48.8M+20% | 49.4M+7% | 50.1M+5% | 51.4M+6% | 52.2M+7% | 53.8M+9% | 54.2M+8% | 54.9M+7% | 55.6M+7% | 57.1M+6% | n/a | n/a |
Gross profit: 24 periods, Q3 FY20 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 6 periods, Q4 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY20 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Biotechnology nearest Ginkgo Bioworks' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| DNAGinkgo Bioworks | $672.7M | n/m | n/a | 6.0× | −47% | n/m | |
| MGTXMeiraGTx | $884.6M | 13.0× | 18.0× | 2.2× | n/m | 19.9% | |
| VCELVericel | $2.2B | 92.5× | 158× | 7.1× | +23% | 7.9% | |
| PLXProtalix BioTherapeutics | $205.5M | 11.1× | 34.2× | 2.5× | +30% | 23.5% | |
| ADMAAdma Biologics | $2.4B | 15.3× | 21.5× | 4.7× | +8% | 33.0% | |
| Peer median | $1.5B | 14.1× | 27.8× | 3.6× | +23% | 21.7% |
Investors who own it
Investors we follow who held Ginkgo Bioworks at the end of Jun 30, 2026, from their 13F filings.
- Andreas HalvorsenViking Global Investors0.1% of portfolio
- Baillie GiffordBaillie Gifford0.0% of portfolio
More on Ginkgo Bioworks
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .